Dharmacon

Oligonucleotide Synthesis, Modification, and Purification Services Market worth $6.53 Billion by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Tuesday, July 5, 2022

Ltd. announces the release of a market assessment report on the " Global Oligonucleotide Synthesis, Modification and Purification Services Market Oligonucleotide Mfg.

Key Points: 
  • Ltd. announces the release of a market assessment report on the " Global Oligonucleotide Synthesis, Modification and Purification Services Market Oligonucleotide Mfg.
  • According to the latest research by InsightAce Analytic, the global oligonucleotide synthesis, modification, and purification services market is valued at US$ 1.56 billion in 2021, and it is expected to reach US$ 6.53 billion by 2030 with a CAGR of 17.50% during a forecast period of 2022-30.
  • Recently, there has been an augmented interest in involving modified oligoribonucleotides in molecular biology, biochemistry, and medicine.
  • However, the high expenses for the purification process, complex manufacturing procedures, oligo-degradation in the generic research, in-house development of oligonucleotides may hinder the growth of the global oligonucleotide synthesis, modification, and purification services market.

Horizon Discovery Extends Gene Modulation Portfolio with Industry First Synthetic Single Guide RNA and Patent Pending dCas9 Repressor for CRISPR Interference

Retrieved on: 
Monday, March 29, 2021

Horizon Discovery, a PerkinElmer, Inc. (NYSE:PKI) company, today announced that its gene editing and modulation portfolio is expanding to include a new family of CRISPR modulation (CRISPRmod) reagents for CRISPR interference (CRISPRi).

Key Points: 
  • Horizon Discovery, a PerkinElmer, Inc. (NYSE:PKI) company, today announced that its gene editing and modulation portfolio is expanding to include a new family of CRISPR modulation (CRISPRmod) reagents for CRISPR interference (CRISPRi).
  • The new reagents include the first-ever commercially available synthetic single guide RNAs for CRISPRi , as well as a patent-pending, dCas9-SALL1-SDS3 repressor available in mRNA and lentiviral formats.
  • The novel dCas9-SALL1-SDS3 repressor was developed following extensive research and has shown more robust and consistent gene modulation over a longer course of time compared to current-generation CRISPRi products.
  • Horizon Discoverys Dharmacon technology, with its patented siRNA tools, has been the market leader in gene modulation for more than 20 years.